Clinical Trial

Surufatinib Plus Gemcitabine and Nab-paclitaxel vs. Gemcitabine Plus Nab-paclitaxel in Neoadjuvant Therapy for High - Risk Resectable or Borderline Resectable Pancreatic Cancer

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
To explore the efficacy and safety of surufatinib in combination with AG regimen verus AG regimen as peri-operative treatment in high - risk resectable or borderline resectable pancreatic cancer
Protocol Amendment History 1 change
critical Recruitment opened 2026-07-11
Trial Details
NCT Number NCT07436741
Lead Sponsor Tianjin Medical University Cancer Institute and Hospital
Conditions Pancreatic Cancer, Adult
Enrollment 106 participants
Start Date 2026-03-03
Primary Completion 2028-09 (estimated)
Study Completion 2030-03 (estimated)
Updated on ClinicalTrials.gov 2026-07-10